Zolgensma, a treatment for spinal muscular dystrophy, costs $2.1 million for a single dose. The maker “Novartis withheld information for months that lab data had been manipulated…until a month after FDA approval.” The data manipulation was known before FDA approval, but the company withheld the information until after approval. For now, the FDA has stated it should remain on the market. Here is another example of pharmaceuticals being allowed to make profits and not people the priority. Please see the article below in the New England Journal of Medicine.